University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
NCT Number: NCT06673004
Premature ovarian failure, also known as primary ovarian insufficiency (POI), or premature menopause, affects 1-2% of women under 40. The diagnosis is typically made based on high levels of follicle stimulating hormone (FSH) and absent or irregular menstrual periods. It leads to infertility and menopause-like effects (hot flashes and thin bones) due to low estrogen levels. POI can result from various factors such as genetic conditions, autoimmune diseases, or previous medical treatments like chemotherapy.
Treatment of POI usually involves hormone replacement therapy and, if pregnancy is desired, assisted reproductive technologies such as in vitro fertilization (IVF) using an egg donor. However, IVF may not be an option for everyone due to personal, religious, ethical or financial reasons. Recent advances in medicine have identified ovarian tissue transplantation (OTT) as a potential solution. OTT involves transplanting either fresh or frozen ovarian tissue into the pelvic area, where it can begin functioning again. Studies in animals and humans have shown success in restoring hormonal function and even achieving pregnancies in some cases. Initial human trials of ovarian tissue transplants from another individual began with identical twins and have since expanded to include non-identical siblings with compatible tissue matches using immunosuppression. Success rates of OTT have been promising, with multiple live births reported between identical twins. Long-term studies indicate that transplanted tissue can remain functional for up to eight years. Ovarian tissue transplantation offers a promising avenue for women with POI to help restore fertility and hormonal function. Continued research and refinement of tissue techniques are essential to improve outcomes and expand access to this innovative treatment option.
This study will enroll 10 participants who will undergo ovarian tissue transplantation donated by a non-identical sister using an immunosuppression protocol at University Hospitals.
Trial opening soon.
Get Notified21 year–40 year
Female
Interventional
Not applicable
Cleveland, Ohio, 44106, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(Donor):
Inclusion criteria
(Recipient):
Inclusion criteria
(Recipient Male Partner)
Exclusion criteria
(Donor) (to be verified by history and review of the medical chart by the study team)
Exclusion criteria
(Recipient)
Exclusion criteria
(Recipient Male Partner )
Participants will receive donor ovarian tissue with immunosuppression
Time frame: Up to 6 months
Time frame: Up to 3 years
Time frame: Up to 2 years
Contact information is provided by the study sponsor or research team.
University Hospitals Cleveland Medical Center
Other
Ovarian Tissue Allo-Transplantation in the Setting of Primary Ovarian Insufficiency Between Non-Genetically Identical Siblings With Use of Immunosuppression
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05181748
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Athens, Attica, Greece
View Trial DetailsNCT04163640
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Basking Ridge, New Jersey, United States
View Trial DetailsNCT01197456
Breast Cancer, Breast Diseases
La Jolla, California, United States
View Trial DetailsNCT04275700
Diminished Ovarian Reserve, Ovarian Failure
New York, United States
View Trial Details